Neoadjuvant chemotherapy for bladder cancer.

While it is now clear that chemotherapy can contribute to improved outcome for some patients with muscle invasive bladder cancer, selection criteria for this very heterogeneous disease are lacking. The authors make an appeal for a biologically (in contrast to anatomically) based staging system, and urge that perioperative chemotherapy be given with standard combinations with curative intent.